SARS-Cov-2

Pfizer said Tuesday that it is seeking emergency use authorization from the FDA for its investigational COVID-19 pill and will allow generic drug makers to produce the novel antiviral for low- and middle-income countries.

A joint consensus review from the Infectious Diseases Society of America and the American Society for Microbiology outlined the potential role and challenges of SARS-CoV-2 sequencing in clinical care.

Treatment with icosapent ethyl was safe and well-tolerated but did not reduce risk for hospitalization or death among COVID-19 outpatients compared with placebo, though researchers observed favorable trends for benefit.

On Sept. 9, President Joe Biden announced a six-pronged plan to combat a rise in COVID-19 cases that included federal vaccine mandates for roughly 100 million U.S. workers.

WASHINGTON – In this video, Cornelius (Neil) J. Clancy, MD, discusses a presentation he gave at the World Anti-Microbial Resistance Congress on antimicrobial use, stewardship and resistance during the COVID-19 pandemic.

Regeneron said that a single dose of its antibody cocktail REGEN-COV reduced the risk for COVID-19 by nearly 82% up to 8 months after administration in a phase 3 trial.

Pfizer said Friday that its investigational oral antiviral Paxlovid reduced COVID-19-related hospitalizations and deaths by 89% in phase 2/3 study of nonhospitalized adults at high risk for severe disease.

COVID-19 vaccination is less effective in immunocompromised adults than it is in the general population, a large study found, supporting recent recommendations that they receive extra doses.

Last month, in an interview with MSNBC, Peter J. Hotez, MD, PhD, warned that the state of Texas could see a fifth wave of COVID-19 right in time for the holidays.

According to Moderna, the FDA said it will need more time to review the company’s request for an emergency use authorization of its COVID-19 vaccine in adolescents to further review the risk for myocarditis in this population.